Mel Mann, Patient Advocate, Chronic Myeloid Leukemia Survivor, shared on X:
“Asciminib Continues to show higher MMR Rates at 144 Weeks in frontline CML.
Updated ASC4FIRST Phase 3 results confirm superior major molecular response with asciminib versus investigator-selected TKIs in newly diagnosed chronic-phase CML, with a favorable safety profile and more patients remaining on treatment.
The STAMP inhibitor expands first-line options.
New cancer stories every day on YouTube.
Education only – not medical advice.”
You can also read:
